Category Archives: LEDs

Click here to enlarge image

July 12, 2005 – Sometimes it takes a lot to get into the Guinness Book of World Records. At Rice University, it required an astronaut, a U.S. district judge, two Nobel laureates, a cheerleading squad, 100 volunteers, 1,000 bystanders, 63,000 plastic model pieces and $15,000.

OK, all it really needed was two independent witnesses and a few hands to snap the pieces representing atoms into a 1,000-foot-long model of a carbon nanotube. The model, calculated to be in scale with the real thing, will join a few other molecular milestones in the book: a carbon fiber that holds the title as the longest nanotube; a nanotube that qualified as the world’s smallest test tube, and a model of a DNA strand akin to Rice’s.

The inspiration came from a celebration for Nobel Prize winners Robert Curl and Richard Smalley, both chemists at Rice, to honor them for their discovery of fullerenes. Each table at the dinner was decorated with a model of the fullerene’s tubular form, the nanotube.

“People loved them so much they carried them off,” said Wade Adams, director of the Nanoscale Science and Technology Center at Rice and an organizer of the Guinness gala. His colleague Matteo Pasquali suggested having students build a scale model to illustrate the nanotube’s length-to-width ratio. More brainstorming and a desire to do “something outrageous” led to the Guinness idea, Adams said.

Astronaut Tracy Caldwell and U.S. District Judge Lynn Hughes attended the April 22 event as witnesses. The cheerleading squad led the crowd in two nanotube cheers as volunteers assembled the model.

The tube didn’t remain intact for long, though. Parts have been sent to Hewlett-Packard and other sponsors. The Houston Museum of Natural Science will put a segment on display. Rice will retain some as a memorial — along with the record-holding title.

July 11, 2005 — Although revenue and unit shipments of MEMS both rose by 15.2 percent in 2004, the pattern of growth in the sector is changing, according to a report recently issued by EmTech Research, a division of Small Times Media.

While unit shipments are forecast to continue expanding at double-digit rates, revenue increases are expected to fall into the single digits over the next five years, according to the report, Entering a New Phase of Growth: 2005 MEMS Forecast.

The report found that Texas Instruments overtook Hewlett-Packard as the leading supplier of MEMS devices based on 2004 revenues, although HP remained the leader in terms of unit shipments. It also found that the communications market, led by cell phones, will see the biggest gains through 2009 and is projected to nearly quadruple its share of MEMS revenue.

Click here to enlarge image

June 8, 2005 – The Sarbanes-Oxley Act of 2002 is getting mixed reviews on Wall Street and in boardrooms. Advocates argue that the rules help eliminate fraud by making corporate leadership accountable. Critics counter that they place an undue burden on smaller companies and dissuade privately held businesses from going public. Two chief financial officers and one accounting professor took a break from the books to respond to questions posed by Small Times’ Candace Stuart.

Click here to enlarge image

Click here to enlarge image

What adjustments have you made in your day-to-day work to comply with the Sarbanes-Oxley Act?

Click here to enlarge image

Jankowski: We have more formal authorizations in place, particularly with respect to disclosure controls and internal controls. Prior to the passage of the act, we had solid controls that were often exercised informally.

Nanophase is not a large company. We have always operated in an environment where we were confident in our processes and our reporting. Now, we are spending more and more time documenting and testing workflows and controls that used to work effectively without the formalized load atop them.

Sankaran: The largest area of change has been in the documentation of controls. Historically, we found that our controls were generally in place, however, they were not always documented. For example, every payment and journal entry was always reviewed by the appropriate person, however the reviewer was not always diligent in writing their initials to document their review.

Now we always document each control. Also, we’ve communicated the importance of having a strong control environment to all employees, and I’ve seen a noticeable improvement in attitudes toward things like purchasing controls, headcount requisitions, expense reports, etc. Employees have embraced the need for running a well-controlled company.

White: From an educational perspective, the Sarbanes-Oxley Act and the events leading to its passage have had a profound impact on our day-to-day approach to accounting education. As educators, we are working to inform the students of the requirements, teach practical skills necessary for understanding and implementing internal controls, and, hopefully, addressing some of the environmental issues that have led to this point.

In New Mexico, we have seen a large increase in the demand for accounting students to meet the needs of increased internal control. The demand has not only been from public accounting firms and private companies, but also from not-for-profit organizations and governmental entities.

What has been the most difficult section of the act to meet? Why?

Jankowski: Clearly, Section 404, regarding internal controls, has been the most difficult section to implement and live within. This section must be applied, by law, in a similar way among all registrants (SEC-registered companies).

In essence, Nanophase is complying with many of the same rules applied to billion-dollar companies. Although we are allowed a certain measure of “compensating controls” to allow for certain entity size issues, it’s still more or less a one-size-fits-all standard. Absent these requirements, it would be imprudent to build so much overhead, in the form of formalized controls and procedures, in the case of sub-$50 million revenue companies such as ours.

Sankaran: Clearly the first-year documentation requirements are significant. Basically, we had to document all of our business processes in each of our major locations. The good news is that this documentation effort should be much lighter going forward, since we now have the basic process on paper and need only document changes in the processes.

White: The feedback that I’ve heard is that two of the most difficult sections of the act to address have been the assessment and implementation of internal controls and ramifications to corporate governance. The internal control work has been a time-consuming and expensive proposition. A recent auditing trade publication reported that the “big four” public accounting firms doubled their audit revenues primarily due to Section 404 internal control work. Hopefully, much of this will be a nonrecurring upfront investment.

On the corporate governance side, the act increases the responsibilities of corporate board members. There is a perception that the act and the associated events have also increased the risk of corporate board membership. The combination may have the effect of making it more difficult to recruit board members.

Has the act added costs or other burdens to your company?

Jankowski: The act has added tremendous costs in implementation as well as in ongoing expenses. We will spend six-figure money every year to remain in compliance with the act as it stands. At some point, we may be required to add staffing or additional consulting time, or both, to keep up with the requirements that have been legislated.

Sankaran: Without a doubt. We spent more than $800,000 (greater than 1 percent of our total annual revenue) on our Sarbanes-Oxley Act program in the first year. These costs were for hiring an internal audit director, outside consultants, internal effort and audit fees.

White: The increase in demand for accounting positions likely indicates a shift of business resources to financial reporting and internal control activities. Recently, The Wall Street Journal reported that year-over-year ongoing audit fees had increased by 40 percent for Dow Jones Industrial Average firms.

An increase in cost due to the act is universal across companies. Opportunities for internal savings are firm-specific. For instance, I am familiar with a firm that used the act as the catalyst to replace an outdated inventory control system. The expense may be chalked up to Sarbanes-Oxley; however, it should produce long-term benefits. On the other hand, if the internal control work is just documenting already existing controls, the internal cost benefit may be small.

The SEC is exploring the idea of tailoring the law to the size of the company. Is that a welcome development?

Jankowski: That is an excellent idea. Size consideration should consider revenue volume as well as market capitalization, at a minimum. It does not benefit shareholders to have small companies forced to carry large overhead loads to comply with laws that were not truly designed with them in mind.

Sankaran: As both an investor and a CFO, I believe that these requirements should apply equally to all publicly traded companies, regardless of size.

White: I think it is a welcome development. The nature of the act provides implementation economies of scale related to transaction volume and dollar amount. The resulting impact is smaller to a very large public company than to a smaller firm.

The act may also create a barrier to businesses seeking funding. An exit strategy via an IPO is now more expensive. Business plans have to give consideration to the resource allocations necessary to create a sufficient internal control infrastructure. Firms may balk at incurring these extra costs.

If you could convince the SEC to allow one change in the law, what would that change be and why?

Jankowski: I would have Section 404 of the act allow for much less formalized internal controls in the case of smaller companies.

Without legislative relief, these added costs are going to keep small entrepreneurial companies out of the public capital markets. There will surely be fewer companies like Intel, Amazon.com, and Genentech building our economy without the support of a willing IPO market. If the cost of being public continues to mount, the bar required to take companies public will be much higher in the future. This will stifle creativity and create a risk-averse investment culture.

We would be better off as a society to disclose the risks of investing in entrepreneurial companies clearly, then let the capital markets value these small companies with the full knowledge that they represent a riskier investment, with a potentially greater return, than larger more stable companies. A limited Sarbanes-Oxley class of registrants would then represent one more factor in an investor’s decision-making process.

Sankaran: Currently, companies are documenting, testing and auditing nearly all business processes and their related controls. However, the act was intended to focus solely on controls over financial reporting. The Public Company Accounting Oversight Board and the audit industry have interpreted the act very broadly, to include nearly every activity within the company.

For example, companies are required to document, test and audit their controls over the hiring process, personnel reviews and executive management meetings/minutes. These areas have little or no relationship to the company’s financial statements. This broadening of the scope of the Sarbanes-Oxley Act is why the effort and cost has been so much larger than anticipated.

If we focused on the intended controls over financial reporting processes, I believe that financial results and reports would be far more reliable and Sarbanes-Oxley Act implementation costs would have been significantly lower.

White: I think an area of discussion that makes a lot of sense is addressing the level of allowable interaction of companies and their auditors in discussing implementation issues. If learning-curve benefits are going to be achieved for smaller firms, auditors must be allowed to offer their expertise without fear of compromising independence.

Has Sarbanes-Oxley increased investor confidence as intended?

Jankowski: I don’t think that it has. In our case, we completed our 2004 Sarbanes-Oxley audit having found no material weaknesses. Although we were proud of the audit findings, they didn’t seem to have a significant impact on our stock.

Sankaran: I’ve not heard any direct feedback from the investment community. Interestingly, the market reaction to the first Sarbanes-Oxley Act audit reports has been mixed. I think the jury is still out.

White: I think a strong argument can be made that Sarbanes-Oxley type rules would not have stopped the upper management abuses of the late 1990s and early 2000s. It is hard to say if Sarbanes-Oxley has increased investor confidence. The ultimate proof is in the willingness of investors to commit money.

July 6, 2005 – In the second quarter, Semiconductor Manufacturing International Corp. (SMIC) ran its capacity at an 86% rate, higher than the 84% recorded by foundry Taiwan Semiconductor Manufacturing Co., a Merrill Lynch & Co.’s study shows, according to Taiwan Economic News.

United Microelectronics Corp. (UMC) and Chartered Semiconductor Manufacturing scored 60% and 65%, respectively.

Merrill Lynch attributed SMIC’s high capacity utilization rate to its aggressive weighting in DRAM (dynamic random access memory) production, a measure expected to help the firm quickly boost defect-free ratio at its 300mm silicon-wafer factory.

This production accounted for 35% of SMIC’s total capacity last quarter, increasing from the 20% it scored in the fourth quarter last year. Throughout this year, contract DRAM production will constitute around 30% of the company’s total capacity, compared with the average 20% it reported throughout last year, thanks to increasing outsourcing orders from European DRAM chipmaker Infineon Technologies and Japanese DRAM chipmaker Elpida Memory.

Merrill Lynch pointed out that SMIC was doing everything it could to boost capacity utilization at its 300mm fab. The company, Merrill Lynch said, planned to boost its 300mm capacity to account for 24% of its total capacity in the first quarter next year from last year’s 12%.

TAMPA, FL, USA–05 July 2005–Three different sessions addressing Good Automated Manufacturing Practice (GAMP) issues will highlight ISPE’s Chicago Training Series, scheduled for 22-25 August at the Eaglewood Conference Resort and Spa in Itasca, Illinois. ISPE provides a wide range of Member-driven educational programs and resources to pharmaceutical industry practitioners worldwide, and is the originator and owner of all GAMP programs.

The Chicago Training Series will open on 22 August with a meeting of the GAMP Americas Forum, a one-day session led by Arthur (Randy) Perez, Executive Expert, QA, Novartis Pharmaceuticals Corporation. The GAMP Americas Forum is open to all pharmaceutical manufacturing professionals, and attendees will have the opportunity to participate in the creation and sharing of computer systems validation and compliance guidance, recommendations, and example practices.

The GAMP Americas Forum will be followed over the next four days by 10 training sessions including a course based on ISPE’s upcoming GAMP Good Practice Guide: IT Infrastructure Control and Compliance, and one focusing on the basics of computer systems validation using GAMP 4. Other courses will focus on such topics as pharmaceutical GMPs, water systems, cleaning, technology transfer, and biopharmaceutical process development. For complete descriptions of each course and to register on-line, visit www.ispe.org/goto_chicagotraining.

ISPE Chicago Training Series: Schedule at a Glance

22 August
* GAMP Americas Forum

22-23 August
* Cleaning Fundamentals for the Pharmaceutical Industry
* GMP Fundamentals for the Pharmaceutical Industry
* Pharmaceutical Water Generation Systems (Includes Webinar)
* Technology Transfer for Finished Dosage Forms, Oral Solids, and Sterile Liquids

23 August
* GAMP Good Practice Guide: Infrastructure

24-25 August
* Basic Principles of Computer Systems Validation Using GAMP 4
* Beyond the Fundamentals-An In-depth Review of GMP for the Pharmaceutical Industry
* Biopharmaceutical Process Development (Includes Webinar)
* Cleaning Validation Principles and Practices
* Pharmaceutical Water Storage, Distribution, System Operation and Validation

About GAMP
GAMP is a product of the GAMP Forum, a technical sub-committee of ISPE whose mission is to promote understanding of the regulation and use of automated systems within healthcare industries. The GAMP Forum’s strategy for computer systems compliance is described in the GAMP Guide for Validation of Automated Systems in Pharmaceutical Manufacture – GAMP 4, an ISPE technical publication which provides a basic framework for validation and addresses considerations unique to particular classes of systems. Since the publication of GAMP 4 in late 2001, several GAMP Special Interest Groups (SIGs) have developed Good Practice Guides addressing these special considerations and systems classes. The GAMP Good Practice Guides include:
* GAMP Good Practice Guide: Calibration Management
* GAMP Good Practice Guide: Validation Process Control Systems (VPCS)
* GAMP Good Practice Guide: Legacy Systems (Published in Pharmaceutical Engineering, Vol. 23, No. 6)
* GAMP Good Practice Guide: A Risk-Based Approach to Compliant Electronic Records and Signatures
* GAMP Good Practice Guide: Validation of Laboratory Computerized Systems

About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is the Society of choice for nearly 23,000 pharmaceutical manufacturing professionals in 80 countries. ISPE aims to be the catalyst for “Engineering Pharmaceutical Innovation” by providing Members with opportunities to develop technical knowledge, exchange practical experience, and collaborate with global regulatory agencies. Founded in 1980, ISPE has worldwide headquarters in Tampa, Florida; an Asia Pacific office in Singapore; a European office in Brussels, Belgium; and Affiliates and Chapters in 18 countries around the world. Visit www.ispe.org for additional Society news and information.
# # #
GAMP is a registered trademark of ISPE.

July 6, 2005 — Nanosphere Inc., a Northbrook, Ill., nanotechnology-based life sciences company, announced that Gregory Shipp has joined the company as its first vice president of medical affairs.

Shipp brings experience in medical, clinical and regulatory affairs management. The appointment comes as Nanosphere prepares to introduce Verigene, a system to enable ultra-sensitive detection of DNA, RNA and proteins on a single platform.

Most recently, Shipp was medical director and chief medical officer for i-STAT Corp., an Abbott Point-of-Care division, where he managed relations with laboratory medical directors and clinical physicians domestically and abroad. He also created awareness of point-of-care testing benefits through the development of post-market clinical studies.

Prior to i-STAT, Shipp was clinical affairs director for Boston Scientific Medi-tech, where he managed the clinical evaluation of an implantable abdominal aortic stent-graft across 26 sites. Before joining Boston Scientific, he was senior medical officer for Bio-Reg Associates. There, he led clinical studies of medical devices in the areas of ophthalmology, plastic surgery, urology and bone physiology.

BY JEFFREY C. DEMMIN

The major assembly and test subcontractors started 2005 with financial results that were surprisingly uniform and generally as projected, but they were negative by most measures. Most companies were optimistic for the rest of 2005, though, with about 10% growth predicted for the second quarter.

ASE, the largest subcontractor, cooled off significantly in the first quarter of 2005. It had the largest revenue drop among the four largest subcons at 12.3%, although it was only slightly higher than the drop at SPIL and STATS ChipPAC. Even with revenue shrinking in Q1 2005, it was still up 14.5% from a year ago, which reflects the excellent year ASE had in 2004.


Figure 1. Quarterly revenue trends at the four largest assembly and test subcontractors since the beginning of 2002. For reference only, up to and including 2Q04, data for STATS ChipPAC is the sum of STATS data and ChipPAC data.
Click here to enlarge image

Amkor had the smallest revenue drop among the top subcons, slipping just 7.9% compared to the fourth quarter of 2004. Amkor’s peak quarterly revenue (Q1 2004) came two quarters earlier than ASE’s or SPIL’s (Q2 2004 vs. Q4 2004), so Amkor’s slide has had a chance slow down (Figure 1). Amkor had a big loss for the quarter (Table 1), although a good portion of that was due to legal expenses. Amkor chairman and CEO James Kim had an optimistic view of 2005. The first quarter revenue was actually at the high of projections, and they see 10 to 13% growth in Q2. Kim says that the “results reflect a bottoming out of the current semiconductor industry correction.” He also predicts higher than average growth for Amkor compared to the rest of the industry in 2005 and 2006, expressing confidence in the growth initiatives begun in 2004.


Table 1. Revenue, revenue growth, and other financial metrics at the four largest assembly and test subcontractors.
Click here to enlarge image

SPIL, the steadiest performer in the group, saw its quarterly revenue drop for the first time since Q1 2003. The 11.9% fall was coincidentally identical to the drop this quarter at STATS ChipPAC. SPIL’s profit stood out from the crowd, though, since they still managed to make $37.8 million, by far the best among the top subcons. SPIL’s gross margin also led the pack, at 14.8% compared to right around 10% for the other three. A factor in this achievement is likely the high utilization rates at SPIL’s factories. For packaging activities, capacity utilization was 83%, which was down from the previous quarter but still higher than the competition, which was typically in the 60 to 70% range. SPIL’s test utilization was also strong at 80%.

STATS ChipPAC was generally the middle performer in the group of top subcons. Revenue change for the quarter was the same as SPIL (down 11.9%), and the quarterly loss was between that of ASE and Amkor. Tan Lay Koon, STATS ChipPAC’s president and CEO, was perhaps the most optimistic, projecting 10 to 15% revenue growth in the second quarter. He says, “We are gaining increased confidence in our prospects for the second half of the year due to improved inventory levels, general stability in demand from a majority of our customers, and an expected return to more healthy utilization levels.”

The largest packaging and test subcons appear to have handled the downturn well. There has been no feeling of panic during the “negative growth,” and most companies believe that they are on the upswing. As shown in Figure 1, the fall in quarterly revenue from the 2004 peak for each company is actually relatively small compared to the growth leading up to it. The overall long-term trend is quite positive.

Click here to enlarge image

JEFFREY C. DEMMIN, director of advanced programs, may be contacted at Tessera Technologies Inc., 3099 Orchard Dr., San Jose, CA 95134; (408) 383-3691; e-mail: [email protected].

June 28, 2005 Cambrios Technologies Corp. named Xina Quan vice president of research and development. Quan will spearhead all R&D and product development activities for Cambrios. Cambrios, of Mountain View, Calif., is harnessing biological systems for the synthesis of materials for manufacturing solid-state electronics.

Before joining Cambrios, Quan managed the product development and release of new high-power white light emitting diode products for cell-phone camera flash applications at Lumileds Lighting. She also spent more than 20 years with Bell Laboratories leading the development of new packaging materials and processes for telecommunications applications before joining Digilens, where she was chief technology officer and VP of R&D.

‘A federal initiative as ambitious as the Manhattan Project is needed to protect the nation from infectious diseases.’ — Senator Bill Frist, June 1, 2005, Harvard Medical School

DENVER, June 24, 2005 (PRIMEZONE) — The National Foundation for Infectious Disease’s annual meeting on Antimicrobial Resistance (NFID) will host experts presenting the latest research in the ongoing battle against the growing threat of bacterial infections that are increasingly resistant to available antibiotics. Dr. Paul Savage, Professor of Chemistry and Biochemistry at Brigham Young University (BYU) will present data on a new category of antibiotics under development by Ceragenix Pharmaceuticals that have the potential to be developed into new therapies for antibiotic resistant bacterial infections such as vancomycin resistant staphylococci (VRSA), vancomycin resistant enterococci (VRE) and pseudomonas infections in cystic fibrosis patients that are resistant to tobramcyin.

Dr. Savage will be available to discuss the data presented in two poster presentations to interested media and the medical community on June 27th at 5:30 p.m. at the NFID conference at the Hyatt Regency Hotel, Bethesda, Md. Both presentations will demonstrate the effectiveness of a new category of antibiotics against certain drug resistant bacteria.

Breakthrough research at BYU has led to the development of Cationic Steroid Antibiotics (CSAs), which mimic the naturally occurring peptides that protect the body against bacteria, viruses, and cancer.

The first presentation by Dr. Savage concerns CSA-13 activity against vancomycin resistant bacterial infections. The second poster will present important data about tobramycin resistant pseudomonas infections from Cystic Fibrosis patients. Both represent promising data in combating lethal strains of antimicrobial resistant bacteria

The natural peptides mimicked by CSAs are the result of millions of years of evolutionary forces and are a form of endogenous antibiotics that do not trigger antibiotic resistance. The presence of these naturally occurring peptides was first discovered 20 years ago. Since then, isolating, purifying and finally synthesizing these compounds in a commercially viable formula has been a long-standing challenge in infectious disease research.

Long-term reliance on antibiotics, and the failure to produce new classes of antibiotics in recent years, has created a looming national crisis. Around the world, governments and nations are recognizing a potential catastrophe, and taking initial measures to address this growing concern. For example, Britain has the second-highest prevalence of methycillin resistant staphylococci (MRSA) in Europe, after Greece. About 46 percent of all staph infections contracted in British hospitals are MRSA. Now, MRSA has found its way into the political arena, with Tony Blair’s government promising to slash infection rates, an issue in the heated British election campaign.

Dr. Savage’s data will provide new insight into the battle against the high number of antibiotic resistant infectious diseases and give new hope for abating the crisis. The NFID conference at the end of June is highly anticipated and will be attended by the most influential names in the scientific and medical communities.

About Cationic Steroid Antibiotics

Cationic Steroid Antibiotics (CSAs) act as potent antibiotics against gram-negative and gram-positive bacteria, and can be used alone or with conventional antibiotics. Extensive in-vitro testing has shown that CSAs are highly effective at very low concentrations against multi-drug resistant strains of Pseudomonas aeruginosa, Salmonella and other potentially lethal bacteria such as methicillin-resistant staph aureus (MRSA) and vancomycin resistant staph aureus (VRSA). The technology is covered by two U.S. patents (6,350,738 and 6,486,148) and has been the subject of more than 10 peer-reviewed journal articles.

About Ceragenix

Ceragenix Pharmaceuticals (OTCBB:OSCE) is a development stage healthcare company focused on dermatology, infectious diseases and oncology. Ceragenix’s patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California, is the platform for the development of two prescription topical creams — Epiceram(tm) and NeoCeram(tm) — that form human-identical skin barriers. Defects in the skin’s barrier function play critical roles in the pathogenesis of skin diseases such as eczema, irritant contact dermatitis and other common skin disorders. The Company’s patented Cationic Steroid Antibiotic (CSA) technology provides the basis for its novel antimicrobial medical device coating that may be attached to various medical devices to provide potentially long duration antimicrobial activity. Ceragenix also plans to develop CSAs for use as topical and systemic antibiotic therapies in the treatment of skin infections (MRSA), burn wound infections, eye infections and other indications.

Forward-Looking Statements

This press release may contain forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the following: the ability of the company to raise sufficient capital to finance its planned pharmaceutical activities, receiving the necessary marketing clearance approvals from the FDA, successful clinical trials of the company’s planned products, the ability of the company to commercialize its planned products, market acceptance of the company’s planned products, and the company’s ability to successfully compete in the marketplace. Although management believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements, the inclusion of such information should not be regarded as a representation by the company or any other person that the objectives and plans of the company will be achieved. For further information, please see the company’s filings with the SEC, including its Forms SB-2, 10-KSB, 10-QSB and 8-K. The company assumes no obligation to update its forward-looking statements to reflect actual results or changes in factors affecting such forward-looking statements.

CONTACT:
Ceragenix Pharmaceuticals
Steven S. Porter
Chief Executive Officer
720-946-6440

The Investor Relations Group
Investor Contact:
Kathryn McNeil
John Nesbett

Media Contact:
Stephanie Schroeder
Janet Vasquez
212-825-3210

June 22, 2005 – Aixtron AG has received an order from Hangzhou Silan Azure Optoelectronics Co. Ltd., Hangzhou, China, for an AIX 2400G3 HT and a 19×2″ Thomas Swan close-coupled showerhead system. Silan Azure, a new LED start-up, plans to mass produce high brightness LEDs with Aixtron and Thomas Swan thin-film growth systems.

Silan Azure is a joint venture of Hangzhou Silan Microelectronics Joint-stock Co. Ltd., a publicly traded company in China specializing in designing, developing and manufacturing ICs. Silan Azure will use the two mass production MOCVD systems for the manufacturing of GaN based LEDs. Silan Azure’s product line will cover both epi wafer growth and chip processing. Silan